Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAM01 Gene Therapy in Severe Sickle Cell Disease
NCT07432867Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2026
- Primary completion
- Feb 2032
- Modality
- Gene Editing, Gene Silencing, RNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of DREAM01 in sickle cell disease (SCD), sponsored by Assistance publique - Hôpitaux de Paris. Started Feb 2026; status: recruiting.
02
Drugs
DREAM01
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07432867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07432867.